相似文献
1
Cholesterol 24-Hydroxylation by CYP46A1: Benefits of Modulation for Brain Diseases.
Neurotherapeutics. 2019 Jul;16(3):635-648. doi: 10.1007/s13311-019-00731-6.
2
Cholesterol-metabolizing enzyme cytochrome P450 46A1 as a pharmacologic target for Alzheimer's disease.
Neuropharmacology. 2017 Sep 1;123:465-476. doi: 10.1016/j.neuropharm.2017.06.026. Epub 2017 Jun 24.
3
Brain Acetyl-CoA Production and Phosphorylation of Cytoskeletal Proteins Are Targets of CYP46A1 Activity Modulation and Altered Sterol Flux.
Neurotherapeutics. 2021 Jul;18(3):2040-2060. doi: 10.1007/s13311-021-01079-6. Epub 2021 Jul 7.
4
CYP46A1 Activation by Efavirenz Leads to Behavioral Improvement without Significant Changes in Amyloid Plaque Load in the Brain of 5XFAD Mice.
Neurotherapeutics. 2019 Jul;16(3):710-724. doi: 10.1007/s13311-019-00737-0.
5
CYP46A1 activation by low-dose efavirenz enhances brain cholesterol metabolism in subjects with early Alzheimer's disease.
Alzheimers Res Ther. 2022 Dec 29;14(1):198. doi: 10.1186/s13195-022-01151-z.
6
Transcriptional and post-translational changes in the brain of mice deficient in cholesterol removal mediated by cytochrome P450 46A1 (CYP46A1).
PLoS One. 2017 Oct 26;12(10):e0187168. doi: 10.1371/journal.pone.0187168. eCollection 2017.
7
In Vitro Activation of Cytochrome P450 46A1 (CYP46A1) by Efavirenz-Related Compounds.
J Med Chem. 2020 Jun 25;63(12):6477-6488. doi: 10.1021/acs.jmedchem.9b01383. Epub 2019 Nov 3.
8
Cholesterol 24-hydroxylase: Brain cholesterol metabolism and beyond.
Biochim Biophys Acta. 2016 Dec;1861(12 Pt A):1911-1920. doi: 10.1016/j.bbalip.2016.09.011. Epub 2016 Sep 20.
9
CYP46A1-dependent and independent effects of efavirenz treatment.
Brain Commun. 2020 Oct 29;2(2):fcaa180. doi: 10.1093/braincomms/fcaa180. eCollection 2020.
10
Mapping of the Allosteric Site in Cholesterol Hydroxylase CYP46A1 for Efavirenz, a Drug That Stimulates Enzyme Activity.
J Biol Chem. 2016 May 27;291(22):11876-86. doi: 10.1074/jbc.M116.723577. Epub 2016 Apr 7.
引用本文的文献
1
Increased 25-hydroxycholesterol as an indicator for patients with vestibular neuritis.
Front Neurol. 2025 Jun 20;16:1600185. doi: 10.3389/fneur.2025.1600185. eCollection 2025.
2
Associations between plasma 24(S)-hydroxycholesterol and neuropsychological profile in fragile X syndrome.
J Lipid Res. 2025 Mar 27;66(5):100787. doi: 10.1016/j.jlr.2025.100787.
3
Cholesterol-modifying strategies for Alzheimer disease: promise or fallacy?
Expert Rev Neurother. 2025 May;25(5):521-535. doi: 10.1080/14737175.2025.2483928. Epub 2025 Apr 3.
4
Brain Cytochrome P450: Navigating Neurological Health and Metabolic Regulation.
J Xenobiot. 2025 Mar 14;15(2):44. doi: 10.3390/jox15020044.
5
25-Hydroxycholesterol modulates microglial function and exacerbates Alzheimer's disease pathology: mechanistic insights and therapeutic potential of cholesterol esterification inhibition.
J Neuroinflammation. 2025 Feb 25;22(1):50. doi: 10.1186/s12974-025-03357-y.
6
The cholesterol 24-hydroxylase CYP46A1 promotes α-synuclein pathology in Parkinson's disease.
PLoS Biol. 2025 Feb 18;23(2):e3002974. doi: 10.1371/journal.pbio.3002974. eCollection 2025 Feb.
7
Role of cholesterol in modulating brain hyperexcitability.
Epilepsia. 2025 Jan;66(1):33-46. doi: 10.1111/epi.18174. Epub 2024 Nov 2.
8
Calycosin-7-O-β-D-Glucoside Ameliorates Palmitate-Induced Lipid Accumulation in HT22 Cells.
Actas Esp Psiquiatr. 2024 Oct;52(5):641-652. doi: 10.62641/aep.v52i5.1723.
9
Association between aromatic amines and serum neurofilament light chain as a biomarker of neural damage: a cross-sectional study from NHANES.
Front Public Health. 2024 Sep 24;12:1344087. doi: 10.3389/fpubh.2024.1344087. eCollection 2024.
10
Cholesterol metabolism: physiological versus pathological aspects in intracerebral hemorrhage.
Neural Regen Res. 2025 Apr 1;20(4):1015-1030. doi: 10.4103/NRR.NRR-D-23-01462. Epub 2024 Apr 3.
本文引用的文献
1
Cholesterol Metabolism Is a Druggable Axis that Independently Regulates Tau and Amyloid-β in iPSC-Derived Alzheimer's Disease Neurons.
Cell Stem Cell. 2019 Mar 7;24(3):363-375.e9. doi: 10.1016/j.stem.2018.12.013. Epub 2019 Jan 24.
2
Brain cholesterol metabolism and Parkinson's disease.
Mov Disord. 2019 Mar;34(3):386-395. doi: 10.1002/mds.27609. Epub 2019 Jan 25.
3
Preferential enhancement of GluN2B-containing native NMDA receptors by the endogenous modulator 24S-hydroxycholesterol in hippocampal neurons.
Neuropharmacology. 2019 Apr;148:11-20. doi: 10.1016/j.neuropharm.2018.12.028. Epub 2018 Dec 27.
4
Higher serum cholesterol and decreased Parkinson's disease risk: A statin-free cohort study.
Mov Disord. 2018 Aug;33(8):1298-1305. doi: 10.1002/mds.27413. Epub 2018 Aug 25.
5
The level of 24-hydroxycholesteryl esters decreases in plasma of patients with Parkinson's disease.
Neurosci Lett. 2018 Apr 13;672:108-112. doi: 10.1016/j.neulet.2018.02.041. Epub 2018 Feb 24.
6
Intracellular Cholesterol Trafficking and Impact in Neurodegeneration.
Front Mol Neurosci. 2017 Nov 17;10:382. doi: 10.3389/fnmol.2017.00382. eCollection 2017.
7
Transcriptional and post-translational changes in the brain of mice deficient in cholesterol removal mediated by cytochrome P450 46A1 (CYP46A1).
PLoS One. 2017 Oct 26;12(10):e0187168. doi: 10.1371/journal.pone.0187168. eCollection 2017.
8
Possible anti-depressant effect of efavirenz and pro-depressive-like effect of voriconazole in specified doses in various experimental models of depression in mice.
Pharmacol Rep. 2017 Oct;69(5):1082-1087. doi: 10.1016/j.pharep.2017.04.018. Epub 2017 May 1.
9
Cholesterol-metabolizing enzyme cytochrome P450 46A1 as a pharmacologic target for Alzheimer's disease.
Neuropharmacology. 2017 Sep 1;123:465-476. doi: 10.1016/j.neuropharm.2017.06.026. Epub 2017 Jun 24.
10
cytochrome P450 46A1 (CYP46A1) activation by neuroactive compounds.
J Biol Chem. 2017 Aug 4;292(31):12934-12946. doi: 10.1074/jbc.M117.794909. Epub 2017 Jun 22.
Zotero 插件